Incidence and predictors of adverse drug events in an African cohort of HIV-infected adults treated with efavirenz

GERMS

Volumn 5, Issue 3, 2015, Pages 83-91

  Abah, Isaac Okoh ^a   Akanbi, Maxwell ^a   Abah, Mercy Enuwa ^a   Finangwai, Amos Istifanus ^a   Dady, Christy W ^a   Falang, Kakjing Dadul ^a   Ebonyi, Augustine Odoh ^a   Okopi, Joseph Anejo ^a   Agbaji, Oche Ochai ^a   Sagay, Altiene Solomon ^a   Okonkwo, Prosper ^b   Idoko, John A ^c   Kanki, Phyllis J ^d  

^a UNIVERSITY OF JOS   (Nigeria)

^b APIN PUBLIC HEALTH INITIATIVES   (Nigeria)

^c NATIONAL AGENCY FOR THE CONTROL OF AIDS   (Nigeria)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Adverse drug reaction; Africa; Antiretroviral therapy; Efavirenz; Neuropsychiatric

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; DIDANOSINE; EFAVIRENZ; HEPATITIS B ANTIGEN; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AFRICAN; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DIARRHEA; DIZZINESS; DRUG INDUCED DISEASE; ENZYME IMMUNOASSAY; FATIGUE; FEMALE; FLOW CYTOMETRY; GYNECOMASTIA; HALLUCINATION; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPIGMENTATION; HYPERSENSITIVITY; JAUNDICE; LIPOATROPHY; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MENTAL DISEASE; MORBIDITY; MYALGIA; NAUSEA AND VOMITING; NIGHTMARE; PARESTHESIA; RASH; RESTLESSNESS; RETROSPECTIVE STUDY; SCORING SYSTEM; SEIZURE; SKIN TINGLING; SOMNOLENCE; SPEECH DISORDER;

EID: 84940778278     PISSN: None     EISSN: 22482997     Source Type: Journal    
DOI: 10.11599/germs.2015.1075     Document Type: Article

References (31)

1. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999;341:1865-73. [CrossRef] [PubMed]
2. Maggiolo F. Efavirenz: a decade of clinical experience in the treatment of HIV. J Antimicrob Chemother 2009;64:910-28. [CrossRef] [PubMed] [FullText]
3. Staszewski S, Gallant J, Pozniak AL, et al. Efficacy and safety of tenofovir DF (TDF) versus stavudine (d4T) when used in combination with lamivudine and efavirenz in antiretroviral-naive patients: 96-week preliminary interim results. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston. Abstract 564b.
4. Fumaz CR, Tuldra A, Ferrer MJ et al. Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens. J Acquir Immune Defic Syndr 2002;29:244-53. [CrossRef] [PubMed]
5. Hawkins T, Geist C, Young B et al. Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients. HIV Clin Trials 2005;6:187-96. [CrossRef] [PubMed]
6. Agbaji OO, Agaba PA, Ekeh PN, et al. Efavirenz-induced gynecomastia in HIV-infected Nigerian men: A report of six cases. Journal of Medicine and Medical Sciences 2011;2(11):1221-4.
7. Bartlett JA, Chen SS, Quinn JB. Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview. HIV Clin Trials 2007;8:221-6. [CrossRef] [PubMed]
8. Spire B, Carrieri P, Garzot MA, L'henaff M, Obadia Y; TRT-5 Group. Factors associated with efavirenz discontinuation in a large community-based sample of patients. AIDS Care 2004;16:558-64. [CrossRef] [PubMed]
9. Barrett JS, Joshi AS, Chai M, Ludden TM, Fiske WD, Pieniaszek HJ Jr. Population pharmacokinetic meta-analysis with efavirenz. Int J Clin Pharmacol Ther 2002;40:507-19. [CrossRef] [PubMed]
10. Pfister M, Labbe L, Hammer SM, et al. Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrob Agents Chemother 2003;47:130-7. [CrossRef] [PubMed] [FullText]
11. Molina JM, Ferchal F, Rancinan C, et al. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. J Infect Dis 2000;182:599-602. [CrossRef] [PubMed]
12. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach, June 2013. Accessed on: 6 May 2014. Available at: http://apps.who.int/iris/bitstream/10665/ 85321/1/9789241505727_eng.pdf
13. Federal Ministry of Health. National guidelines for HIV and AIDS treatment and care in adolescents and adults. Abuja, Nigeria. 2007. Accessed on: 18 February 2014. Available at: http://www.who.int/hiv/amds/Nigeria_ adult_2007.pdf
14. World Health Organization. A practical handbook on the pharmacovigilance of antiretroviral medicines. Accessed on: 9 June 2014. Available at: http://www.who.int/hiv/ topics/pharmacovigilance/arv_pharmacovigilance_handbook.pdf?ua=1
15. Puzantian T. Central nervous system adverse effects with efavirenz: case report and review. Pharmacotherapy 2002;22:930-3. [CrossRef] [PubMed]
16. Blanch J, Martínez E, Rousaud A, et al. Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz. J Acquir Immune Defic Syndr 2001;27:336-43. [CrossRef] [PubMed]
17. Arendt G, de Nocker D, von Giesen HJ, Nolting T. Neuropsychiatric side effects of efavirenz therapy. Expert Opin Drug Saf 2007;6:147-54. [CrossRef] [PubMed]
18. Cespedes MS, Aberg JA. Neuropsychiatric complications of antiretroviral therapy. Drug Saf 2006;29:865-74. [CrossRef] [PubMed]
19. Hawkins T, Geist C, Young B, et al. Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients. HIV Clin Trials 2005;6:187-96. [CrossRef] [PubMed]
20. Gutiérrez F, Navarro A, Padilla S, et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis 2005;41:1648-53. [CrossRef] [PubMed]
21. Bartlett JA, Chen SS, Quinn JB. Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview. HIV Clin Trials 2007;8:221-6. [CrossRef] [PubMed]
22. Severe P, Leger P, Charles M, et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 2005;353:2325-34. [CrossRef] [PubMed]
23. Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med 2005;143:714-21. [CrossRef] [PubMed]
24. von Giesen HJ, Köller H, de Nocker D, Haslinger BA, Arendt G. Long-term safety and efficacy of NNRTI within the central nervous system. HIV Clin Trials 2003;4:382-90. [CrossRef] [PubMed]
25. Cederfjäll C, Langius-Eklöf A, Lidman K, Wredling R. Gender differences in perceived health-related quality of life among patients with HIV infection. AIDS Patient Care STDS 2001;15:31-9. [CrossRef] [PubMed]
26. Ofotokun I, Pomeroy C. Sex differences in adverse reactions to antiretroviral drugs. Top HIV Med 2003;11:55-9. [PubMed]
27. Turjanski N, Lloyd GG. Psychiatric side-effects of medications: recent developments. Adv Psychiatr Treat 2005;11:58-70. [CrossRef]
28. Foster R, Olajide D, Everall IP. Antiretroviral therapy-induced psychosis: case report and brief review of the literature. HIV Med 2003;4:139-44. [CrossRef] [PubMed]
29. Maxwell S, Scheftner WA, Kessler HA, Busch K. Manic syndrome associated with zidovudine treatment. JAMA 1988,259:3406-7. [CrossRef] [PubMed]
30. Rachlis A, Fanning MM. Zidovudine toxicity. Clinical features and management. Drug Saf 1993;8:312-20. [CrossRef] [PubMed]
31. Price RW, Spudich S. Antiretroviral therapy and central nervous system HIV type 1 infection. J Infect Dis. 2008;197 Suppl 3: S294-S306. [CrossRef] [PubMed] [FullText]